Safety and Efficacy of Fixed-dose Omadacycline Remains Consistent, Regardless of BMI, in CABP Patients

According to a study on phase III trial, that a fixed-dosing omadacycline strategy demonstrates consistent safety and efficacy in patients with community-acquired bacterial pneumonia or CABP, regardless of one’s body mass index or BMI.

Photo: Doctor Reading an X-Ray of Lungs | InStyleHealth


There was a total of 756 patients hospitalized for suspected CABP were randomized to receive intravenous omadacycline or moxifloxacin, with an optional transition to oral, for 7 to 14 days. Of which, 278 patients were of normal weight, 266 were overweight, and 212 were obese.

The clinical success rates 72-120 hours following receipt of the first dose were similar in both treatment arms and across BMI categories: 82.9%, 80.5%, and 76.9% normal weight, overweigh, and obese patients in the omadacycline arm. Corresponding numbers in the moxifloxacin arm were 88.6%, 80.7%, and 76.9%.

Outcomes were consistent in an analysis stratified by diabetes status, with generally similar clinical success rates in the two treatment groups. Patients who attained early clinical success or clinical stability generally showed continued clinical success at 5-10 days after the last dose or post-treatment evaluation.

The safety profiles of omadacycline and moxifloxacin were largely comparable across BMI subgroups and by diabetes history.


Source: Respir Med 2021;184:106442

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post